glp 1 drugs sex drive Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it Are GLP-1 Drugs Quietly Changing

GLP-1 receptor agonists: gastric emptying, procedures, and pancreatic safety

The National Weight Control Registry, which tracks individuals who have successfully maintained significant weight loss, identifies common characteristics including high levels of physical activity, regular breakfast consumption, consistent eating patterns across weekdays and weekends, and frequent self-weighing

Lilly and Novo are trying to increase insurance coverage of GLP-1 drugs for obesity

The problem is that many people who take such drugs quit them within two years because of side effects and the cost

However, GLP-1RAs also modestly reduce systolic blood pressure (SBP) by 24 mmHg (66)